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Abstract
Background: Recent studies have suggested that vitamin D can act on cells in the nervous system. Associations between
polymorphisms in the vitamin D receptor (VDR), age- dependent cognitive decline, and insufficient serum 25
hydroxyvitamin D3 levels in Alzheimer’s patients and elderly people with cognitive decline have been reported. We have
previously shown that amyloid b (Ab) treatment eliminates VDR protein in cortical neurons. These results suggest a
potential role for vitamin D and vitamin D-mediated mechanisms in Alzheimer’s disease (AD) and neurodegeneration.
Vitamin D has been shown to down-regulate the L-type voltage-sensitive calcium channels, LVSCC-A1C and LVSCC-A1D,
and up-regulate nerve growth factor (NGF). However, expression of these proteins when VDR is repressed is unknown. The
aim of this study is to investigate LVSCC-A1C, LVSCC-A1D expression levels and NGF release in VDR-silenced primary cortical
neurons prepared from Sprague-Dawley rat embryos.
Methodology/Principal Findings: qRT-PCR and western blots were performed to determine VDR, LVSCC-A1C and -A1D
expression levels. NGF and cytotoxicity levels were determined by ELISA. Apoptosis was determined by TUNEL. Our findings
illustrate that LVSCC-A1C mRNA and protein levels increased rapidly in cortical neurons when VDR is down-regulated,
whereas, LVSCC-A1D mRNA and protein levels did not change and NGF release decreased in response to VDR down-
regulation. Although vitamin D regulates LVSCC-A1C through VDR, it may not regulate LVSCC-A1D through VDR.
Conclusions/Significance: Our results indicate that suppression of VDR disrupts LVSCC-A1C and NGF production. In
addition, when VDR is suppressed, neurons could be vulnerable to aging and neurodegeneration, and when combined with
Ab toxicity, it is possible to explain some of the events that occur during neurodegeneration.
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Introduction
The name ‘‘vitamin D’’ is a misnomer; in actuallity, vitamin D
(1,25 (OH)2D3) is a multipurpose secosteroid hormone. It consists of
a broken cholesterolbackbone, and it has steroid-like effects, suchas
regulating the expression of over 1,000 genes. Although a relatively
limited number of studies have investigated the genes targeted by
vitamin D in the brain [1,2,3,4,5,6,7,8,9,10,11,12,13,14], the
probable effects of vitamin D on neurotrophic factor production,
oxidative stress mechanisms, Ca
2+ homeostasis and the immune
system are irrefutable. A study on hippocampal neuron cultures
suggest that vitamin D promotes calcium homeostasis by decreasing
the level of L-type voltage-sensitive calcium channels (LVSCC), and
channel density, on the plasma membrane [2]. In addition, vitamin
D is involved in determining neuronal fate via its regulationof nerve
growth factor (NGF) expression [8].
Vitamin D exerts its effects through its nuclear hormone
receptor, vitamin D receptor (VDR) or its membrane receptor,
membrane-associated, rapid-response, steroid-binding protein
(1,25 MARRS) [15]. Recently, it was shown that VDR and the
enzymes involved in bioactivation of vitamin D, are abundantly
expressed in the majority of the central nervous system,
particularly in areas affected by neurodegenerative disorders
[5,8,16,17,18].
Consistent with its expression pattern, there is a correlation
between polymorphisms inVDR, age-dependent cognitive decline
and insufficient vitamin D precursor (25 hydroxyvitamin D3) levels
in serum from AD patients and elderly people with cognitive
decline [19,20,21,22,23]. We have previously shown that poly-
morphisms in VDR may increase the vulnerability to Alzheimer’s
disease (AD) [24]. In addition, we have shown that amyloid b (Ab)
treatment eliminates expression of VDR mRNA and protein in
cortical neurons [25]. Furthermore, we have shown that vitamin D
can protect neurons against Ab-induced toxicity by down-
regulating LVSCC-A1C expression, up-regulating VDR expres-
sion and inducing NGF release [25]. These results indicate that
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ilvitamin D and vitamin D-related mechanisms may function in AD
and neurodegeneration.
Our aim is to determine whether down-regulation of VDR leads
to alterations in the expression of calcium channels and
neurotrophic factors in neurons. To investigate the effects of
VDR down-regulation in some of the neurodegeneration-related
mechanisms, VDR was knocked down in cultured rat cortical
neurons using small interfering RNA (siRNA) induced gene
silencing. The effects on LVSCC-A1C and LVSCC-A1D
expression and NGF levels were investigated after siRNA
treatment to determine the effect that disruption of the vitamin
D-VDR pathway has on these proteins, and whether vitamin D-
induced regulation of these proteins depends on VDR.
Results
Previously, we demonstrated that vitamin D treatment up-
regulates VDR, down regulates LVSCC-A1C and induces NGF
release in cortical neurons [25]. Prior to this study we showed that
expression of LVSCC-A1D mRNA was down-regulated in
vitamin D-treated cortical neurons compared to the untreated
control neurons (p=0.005). Our primary goal in the present study
is to investigate alterations of the LVSCC-A1C, LVSCC-A1D and
NGF in VDR-silenced neurons.
Cytotoxicity and Cell Death Assay
Cytotoxicity and cell death assays were used to determine the
overall effect of short-term VDR silencing on neuronal survival.
Lactate dehydrogenase (LDH), which is an enzyme released in the
extracellular environment in response to membrane damage and/
or oxidative stress-related cell death, was measured to determine
cytotoxicity levels. Terminal deoxynucleotidyl transferase dUTP
nick end labeling (TUNEL) was used to determine whether cell
death occurred as a result of apoptosis.
There was no significant difference in LDH release between
siRNA-treated groups and control groups in cortical neurons after
24 hours of treatment. No significant difference was observed in
the apoptotic index between siRNA-treated groups and control
groups in cortical neurons after 24 hours of treatment. These
results indicated that siRNA treatment did not cause cytotoxicity
or apoptosis.
qRT-PCR results
Quantitative real time-polymerase chain reaction (qRT-PCR)
was used to determine the effects of all treatments on the relative
expression of target genes by measuring mRNA levels. To
determine the specificity of VDR silencing, and the rate of
silencing, three additional control groups [Cyclophiline B (CycB)
siRNA, non-target siRNA and transfection reagent] were used to
treat neurons, in addition to untreated control neurons.
After 6 hours of VDR siRNA treatment, VDR was not silenced.
Alterations in LVSCC-A1C mRNA expression were not detected
in these groups. These data were not presented. After12 hours of
VDR siRNA treatment, VDR mRNA levels were significantly
reduced (Fig. 1A). Significantly higher levels of LVSCC-A1C
mRNA were observed 12 hours after VDR siRNA treatment
(Fig. 2A). After 24 hours of VDR siRNA treatment, there was a
significant reduction in VDR mRNA levels and an increase in
LVSCC-A1C mRNA levels (Table 1). VDR silencing occurred
after both 12 and 24 hours of treatment, and LVSCC-A1C
mRNA expression was up-regulated during the same time periods.
In contrast, LVSCC-A1D mRNA levels did not change after 12
(Fig. 3A) and 24 hours of treatment (p.0.05). These results
indicate that VDR siRNA treatment suppresses VDR expression.
Furthermore, VDR suppression results in increased LVSCC-A1C
mRNA expression, but does not affect LVSCC-A1D mRNA
levels.
Treatment with CycB siRNA (positive control) resulted in
significantly lower levels of CycB mRNA. There were no
significant differences in VDR, LVSCC-A1C or LVSCC-A1D
mRNA levels after 12 and 24 hours of CycB siRNA treatment.
These results indicate that alterations in mRNA expression were
specific to VDR siRNA treatment.
Western Blot results
Western blots were used to determine the efficiency of VDR
silencing at the protein level and to investigate whether changes in
mRNA expression correspond to changes in VDR, LVSCC-A1C
and, LVSCC-A1D protein levels.
VDR silencing was confirmed at the protein level (Fig. 1B and
1C). Higher levels of LVSCC-A1C protein were observed after 12
(Fig. 2B and 2C) and 24 hours of VDR siRNA treatment, in
agreement with the mRNA results. In addition, LVSCC-A1D
protein levels at 12 (Fig.3B and 3C) and 24 hours after VDR
siRNA treatment did not change, consistent with the mRNA
results. Only results from the 12 hour siRNA treatment were given
because the 24 hour siRNA treatment results were similar to the
12 hours results.
VDR siRNA and vitamin D (1,25 (OH)2D3) combined
treatments
Combined treatments with VDR siRNA and vitamin D were
performed to determine the effects of vitamin D treatment on the
expression of genes of interest in VDR-silenced neurons.
VDR mRNA and protein levels were up-regulated in the group
that received 12 hours of 1610
27 M vitamin D after 12 hours of
VDR siRNA treatment (VDR siRNA+ vitamin D) (Fig. 1),
whereas LVSCC-A1C (Fig. 2) and LVSCC-A1D mRNA and
protein (Fig. 3) levels were down-regulated when compared to the
VDR siRNA-treated group. These results indicate that vitamin D
leads to an increase in VDR expression in cortical neurons and
may rapidly regulate target genes by up-regulating VDR
expression after VDR is silenced in neurons.
NGF Assay
We also investigated whether VDR regulation correlates with
the levels of NGF release when the vitamin D-VDR pathway is
blocked. There was no significant difference in NGF protein levels
after 12 hours of siRNA treatment (p.0.05). After 24 hours of
VDR siRNA treatment, there was a significant decrease in NGF
protein levels, whereas there were no significant differences in
NGF protein levels in control groups (Fig. 4). Although the precise
mechanism of how vitamin D contributes to NGF release is
unknown, these results demonstrate that short-term inhibition of
the vitamin D-VDR pathway leads to a decrease in NGF release.
Discussion
According to the Third National Health and Nutrition
Examination Survey (USA), vitamin D deficiency frequently
occurs in a wide range of populations, especially in the
institutionalized and elderly [5,26]. The misperception of vitamin
D as a ‘‘simple vitamin’’ can hide the effects of its deficiency,
which is a significant and on-going problem that has been termed
the ‘‘silent epidemic’’. Vitamin D deficiency has a number of
potential consequences, many of which are still unknown [5,27].
In a number of studies, it has been suggested that vitamin D in
the brain regulates neurotrophic factor production, oxidative stress
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2+ homeostasis and immune system functions
[1,2,3,4,5,6,8,10,11,12,13,14,25]. To investigate the effects of
short-term disruption of the vitamin D-VDR pathway on some of
these mechanisms, the vitamin D receptor (VDR) gene was
knocked down in cortical neurons using siRNAs. Following siRNA
treatment, L-type voltage-sensitive calcium channels A1C
(LVSCC-A1C), and -A1D (LVSCC-A1D) mRNA and protein
levels and NGF production were determined in this study.
VDR was silenced by siRNAs because of the effects that
potential compensatory mechanisms may have in VDR knock-out
animals [28], which could interfere with detection of the direct
effects of VDR silencing in neurons. Vitamin D deficiency can
Figure 1. siRNA-mediated knockdown of VDR. A) Comparison of VDR mRNA levels. VDR siRNA treatment suppressed VDR mRNA
expression. After 12 hours of vitamin D treatment (1610
27 M) applied to VDR-silenced neurons, VDR mRNA levels increased. These results indicate
that vitamin D increases VDR expression in cortical neurons * VDR mRNA levels from VDR-silenced neurons were statistically lower than in the control
groups (p,0.001, p,0.001, p,0.001, p,0.001, respectively). ** VDR mRNA levels from Vitamin D-treated VDR-silenced neurons were statistically
higher than in the VDR siRNA-treated group (p,0.001). B) Western blot detecting VDR protein level. VDR siRNA treatment suppressed VDR
protein expression. After 12 hours of vitamin D treatment (1610
27 M) in VDR-silenced neurons, VDR protein levels increased. Beta actin was used as
the loading control. C) Comparison of VDR protein band intensities relative to Beta actin. The absolute intensities of VDR and Beta actin
protein bands were measured using Image J software, and the relative intensities were calculated from the ratio of VDR to Beta actin absolute
intensities. * VDR protein levels from VDR-silenced neurons were statistically lower than in control groups (p,0.001, p,0.001, p,0.001, p,0.001,
respectively). ** VDR protein levels from vitamin D-treated VDR-silenced neurons were statistically higher than in the VDR siRNA-treated group
(p,0.05). Control: Untreated control group; Vehicle: Transfection reagent-treated control group; Non target siRNA: Non-target siRNA-treated negative
control group; Cyc B siRNA: Cyclophilin B siRNA-treated positive control group; VDR siRNA: VDR siRNA-treated group and VDR siRNA+Vitamin D:
Following 12 hours of VDR siRNA treatment, groups were treated with vitamin D. Data are presented as a mean SD.
doi:10.1371/journal.pone.0017553.g001
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nisms might not work well enough to adapt to vitamin D
deficiency. Currently, there is no information about the effects that
long-term vitamin D deficiency can have on the brain later in life
due to the short life span of VDR knockout mice [29,30]. It has
been suggested that genetic ablation of VDR promotes premature
aging in mice, and that vitamin D homeostasis regulates
physiological aging [29]. Moreover, animals that have a
Figure 2. siRNA-mediated knockdown of VDR induces expression of LVSCC-A1C mRNA and protein. A) Comparison of LVSCC-A1C
mRNA levels. VDR suppression resulted in increased LVSCC-A1C mRNA expression, but the effects of VDR suppression on LVSCC-A1C were
normalized after vitamin D treatment.* LVSCC-A1C mRNA levels from VDR-silenced neurons were statistically higher than in other groups (p=0,015,
p=0,034, p=0,002, p=0,024, respectively). ** LVSCC-A1C mRNA levels were statistically lower than in VDR siRNA-treated group (p=0,013). B)
Detection of LVSCC-A1C protein by western blot. Although LVSCC-A1C protein increased in VDR-silenced neurons, vitamin D treatment
decreased LVSCC-A1C expression to control levels. Beta actin was used as loading control. C) Comparison of LVSCC-A1C protein band
intensities relative to Beta actin. Western blot results were consistent with mRNA results. The absolute intensities were measured using Image J
software, and the relative intensities were calculated from the ratio of LVSCC-A1C to Beta actin absolute intensities. * LVSCC-A1C protein levels from
VDR-silenced neurons were statistically higher compared to control groups (p,0.01, p,0.01, p,0.05, respectively). ** LVSCC-A1C protein levels from
vitamin D-treated VDR-silenced neurons were statistically lower compared to the VDR siRNA-treated group (p,0.001). Control: Untreated control
group; Vehicle: Transfection reagent-treated control group; Non target siRNA: Non-target siRNA-treated negative control group; Cyc B siRNA:
Cyclophilin B siRNA-treated positive control group; VDR siRNA: VDR siRNA-treated group and VDR siRNA+Vitamin D: Following 12 hours of VDR siRNA
treatment, groups were treated with vitamin D. Data are presented as a mean SD.
doi:10.1371/journal.pone.0017553.g002
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ventricles, reduced NGF protein and reduced expression of a
number genes involved in neuronal structure. These observations
demonstrate that transient hypovitaminosis D3 early in life not
only disrupts brain development, but leads to persistent changes in
the adult brain [14].
One of the most crucial changes that occurs in the aging brain is
the disruption of calcium homeostasis [31]. The L-type voltage-
sensitive Ca
2+ channel, examined in VDR repressed neurons in the
present study, is one of the most important proteins in calcium
metabolism, aging and neurodegeneration. Previous studies have
implicated Ca
2+ dysregulation in the aging brain and Alzheimer’s
disease (AD), giving rise to the ‘‘Ca
2+ hypothesis of brain aging and
dementia’’ [32]. Increased LVSCC activity leads to up-regulation
of Ca
2+ related biomarkers in the aging hippocampus, and it has
been implicated as one of the mechanisms related to this
hypothesis. LVSCC down-regulation after vitamin D treatment
in hippocampal and cortical neurons has previously been reported
[2,3,25]. However, there is currently no information about the
regulation of this channel under conditions of VDR repression.
This study reports the effects of VDR silencing, on LVSCC-A1C
expression, which has a substantial role in both aging and
neurodegeneretion in primary cortical neuron cultures. Our
results show that LVSCC-A1C mRNA levels were up-regulated
in VDR siRNA-treated groups after both 12 and 24 hours of
treatment, compared to the control groups. The same trend was
observed when protein levels were analyzed. This marks the first
time that up-regulation of LVSCC-A1C has been shown to be
caused by VDR silencing. In addition, up-regulation of VDR and
down-regulation of LVSCC-A1C and -A1D levels were observed
in the vitamin D-treated VDR siRNA group. In other words,
expression levels of both VDR and LVSCC-A1C in VDR siRNA-
treated groups were normalized to the vitamin D-supplemented
groups. These results support the notion that vitamin D regulates
VDR expression in cortical neurons [33] and that vitamin D
regulates LVSCC-A1C and -A1D expression in neurons [2,3].
Our results also demonstrate that similar mechanisms operate in
cortical and hippocampal neurons.
Regarding our results we may speculate that VDR, not the
vitamin D membrane receptor, regulates LVSCC-A1C expres-
sion. It is also clear that LVSCC-A1C is a VDR-regulated protein.
One of the most important results from this study was that VDR
suppression did not affect LVSCC-A1D mRNA or protein
expression. Although expression of this protein was altered by
supplementation with vitamin D, this regulation might not be from
VDR. As there are some clues that vitamin D triggers some
signaling pathways by its membrane receptor (membrane-
associated, rapid-response, steroid-binding protein; 1,25 MARRS)
[15], we speculate that vitamin D may regulate LVSCC–A1D by
that receptor. Thus, VDR-independent pathways, such as those
dependent on 1,25 MARRS, should be further studied to clarify
the action of this hormone.
Characterization of the short-term response of VDR-silenced
neurons will provide novel data for guiding in vivo experiments to
characterize the long-term effects of vitamin D-VDR pathway
disruption. Based on our findings, we speculate that VDR
knockout mice may not display all the effects that vitamin D has
on vitamin D-regulated proteins because we determined that
LVSCC-A1D may not be regulated by VDR even though it is
regulated by vitamin D. Therefore, VDR and vitamin D
membrane receptor 1,25 MARRS double knock-out mice may
be used to clarify vitamin D action.
Together with its role in calcium metabolism, vitamin D has
been suggested to have protective effects in the nervous system
through regulation of NGF, glial derived neurotrophic factor
(GDNF) and neurotrophins. Regulation of NGF expression by
vitamin D has been demonstrated in several cell types
[1,6,8,11,13,14,17,34]. However, no information has been pub-
lished regarding NGF regulation when VDR has been repressed.
In the present study, there was a significant reduction in NGF
levels after VDR siRNA treatment. NGF is regulated by a variety
of molecules in addition to vitamin D [35]. In our study, NGF
down-regulation was observed when VDR was silenced; this may
provide a molecular explanation for previous in vivo results
demonstrating that animals exposed to transient-early vitamin D
deficiency had reduced NGF protein levels [14]. Interestingly, we
have previously shown that after 48 hours of Ab treatment, there
was a decrease in VDR protein, and after 72 hours of treatment,
there was a decrease in NGF secretion [25]. Together, with the
results of this present study, we speculate that the reduction in
NGF release in Ab-treated cortical neurons may be caused by the
depletion of VDR. Currently, it is not clear whether vitamin D-
mediated regulation of NGF is caused by direct transcriptional
regulation or by another mechanism related to NGF production or
Table 1. The effects of siRNA-mediated knockdown of VDR onVDR and LVSCC-A1C mRNA expression in 24 hour treatment.
Compared groups ***mRNA Expression Std. Error 95% C.I. P(H1) Result
VDR mRNA levels of 24 hour treatment
Cont vs. VDR siRNA 0.350 0.280–0.451 0.246–0.485 0.000 DOWN*
Vehicle vs. VDR siRNA 0.312 0.208–0.452 0.168–0.603 0.000 DOWN
Non Target vs. VDR siRNA 0.338 0.240–0.459 0.222–0.495 0.000 DOWN
CycB siRNA vs. VDR siRNA 0.386 0.270–0.542 0.255–0.556 0.000 DOWN
LVSCC-A1C mRNA levels of 24 hour siRNA treatment
Cont vs. VDR siRNA 2.992 2.150–4.588 1.677–6.186 0.002 UP**
Vehicle vs. VDR siRNA 2.839 1.849–4.221 1.280–7.994 0.001 UP
Non Target vs. VDR siRNA 3.198 1.631–5.679 1.174–6.847 0.003 UP
CycB siRNA vs. VDR siRNA 1.693 1.064–2.725 0.776–3.825 0.014 UP
REST 2008 was used for statistical analysis.
* VDR is DOWN-regulated in sample group (in comparison to control groups).
** LVSCC-A1C is UP-regulated in sample group (in comparison to control groups).
*** Expression values have normalized to the 3 housekeeping genes, GAPDH, HPRT, ACTB.
doi:10.1371/journal.pone.0017553.t001
The Effects of VDR Silencing on Cortical Neurons
PLoS ONE | www.plosone.org 5 March 2011 | Volume 6 | Issue 3 | e17553release. Our results demonstrate, for the first time, that silencing of
the vitamin D receptor leads to down-regulation of NGF in
‘‘cortical neurons’’, suggesting that inefficient utilization of vitamin
D may lead to a reduction of NGF in neurons during the aging
process.
The rapid increase in LVSCC-A1C expression and NGF down-
regulation as a response to VDR silencing indicates that neurons
could be vulnerable to aging and neurodegeneration when there is
a long-term, or permanent, inefficient utilization of vitamin D.
Because both Ab [25] and VDR siRNA-dependent supression of
VDR (current study) have very similar effects on neurons, we
speculate that insufficient vitamin D levels in AD patients, in
addition to depletion of VDR protein by Ab, could give rise to a
series of deleterious effects. When considering the role that vitamin
Figure 3. VDR siRNA-mediated knockdown does not change the expression of LVSCC-A1D mRNA and protein. A) Comparison of
LVSCC-A1D mRNA levels. LVSCC-A1D mRNA levels from VDR-silenced neurons were not different than control groups (p.0.05), but LVSCC-A1D
mRNA levels significantly decreased after vitamin D treatment in VDR-silenced neurons. * LVSCC A1D mRNA levels from vitamin D-treated VDR-
silenced neurons were statistically lower than control levels (p=0,019, p=0,019, p=0,030, p=0,013, respectively) and VDR siRNA-treated groups
(p=0,031). B) Detection of LVSCC-A1D protein by western blot. LVSCC-A1D protein levels did not change in VDR-silenced neurons. Vitamin D
treatment in VDR-silenced neurons led to a decrease in LVSCC-A1D protein levels. Beta actin was used as a loading control. C) Comparison of
LVSCC-A1D protein band intensities relative to beta actin. Western blot results were consistent with mRNA results. The absolute intensities
were measured using Image J software, and the relative intensities were calculated from the ratio of LVSCC-A1D to beta actin absolute intensities.
* LVSCC-A1D protein levels from vitamin D-treated VDR-silenced neurons were statistically lower compared to other groups (p,0.001, p,0.001,
p,0.001, p,0.001, p,0.001, respectively). Control: Untreated control group; Vehicle: Only transfection reagent-treated control group; Non target
siRNA: Non-target siRNA-treated negative control group; Cyc B siRNA: Cyclophilin B siRNA-treated positive control group; VDR siRNA: VDR siRNA-
treated group and VDR siRNA+Vitamin D: Following 12 hours of VDR siRNA treatment, groups were treated with vitamin D. Data are presented as a
mean SD.
doi:10.1371/journal.pone.0017553.g003
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vitamin D may be indispensable in the brain function. Knowledge
regarding the status of the vitamin D membrane receptor protein
in Ab-treated neurons and in models that are both neurodegen-
erative and vitamin D deficient will help us better understand the
action of vitamin D.
Previously, we showed that vitamin D has the potential to
rearrange neuronal calcium homeostasis that has been broken by
Ab or inhibit the toxicity induced by Ab [25]. Thus, vitamin D can
protect neurons against neurotoxicity. In this study, LDH levels
and the apoptotic index of VDR siRNA-treated group did not
differ from control groups. This can be explained by the short time
period of the treatments. This suggests that vitamin D has
protective effects after 24 hours of treatment in primary cortical
neurons.
Consequently, our study demonstrates that vitamin D-VDR
pathway has important roles in brain. NGF, a neuronal survival
molecule that can potentially be used to treat neurodegenerative
diseases [36] is a VDR-regulated protein that is affected by VDR
suppression. Our data support the ‘‘Ca
2+ hypothesis of brain aging
and dementia,’’ and suggest that vitamin D is a crucial part of this
hypothesis. Furthermore, we speculate that some of the toxic
effects induced by Ab, including disruption of calcium homeostasis
and dysregulation of NGF synthesis, may be caused by vitamin D
deficiency and/or the inefficient utilization of vitamin D due to
VDR protein depletion.
Materials and Methods
Preparation of primary cortical neuron cultures
The study was approved by the Animal Welfare and Ethics
Committee of Istanbul University, number 23797/20.09.2006.
The procedures involving experimentation on animal subjects
were performed in accord with both the guidelines of Istanbul
University, and with the National Research Council’s guidelines
for the care and use of laboratory animals.
Neuronal cultures were prepared from the cerebral cortex of
embryonic day 16 (E16) Sprague-Dawley rat embryos as previously
described [25,37]. Briefly, embryos were removed, and the cortex,
excluding the olfactory cortex and the hippocampus, was dissected
and freed of meninges. The cells were plated at a density of 6610
5
cells per dish in Leibovitz 15 (L15) media (GibcoBRL 11415-064,
Invitrogen Inc., New York, USA) containing: 0.1 mg/ml conalbu-
min (Sigma C-7786, Sigma-Alderich Chemie GmbH, Steinheim,
GE), 0.63 mg/ml sodium bicarbonate (GibcoBRL 25080-094,
Invitrogen Inc., New York, USA), 0.1 mM putrescine (Sigma P-
7505, Sigma-Alderich Chemie GmbH, Steinheim, GE), 10 ng/ml
insulin (GibcoBRL 12585, Invitrogen Inc., New York, USA),
30 nM sodium selenite (Sigma S-5261, Sigma-Alderich Chemie
GmbH, Steinheim, GE), 20 nM progesterone (Sigma P-6149,
Sigma-Alderich Chemie GmbH, Steinheim, GE), 20 mM glucose
(Sigma G-7021, Sigma-Alderich Chemie GmbH, Steinheim, GE)
and 10 IU/ml PenStrep (Sigma P-4333, Sigma-Alderich Chemie
GmbH, Steinheim, GE). These cells were then marked as L15+ and
incubated for one day at 37uC and 5% CO2 in a humidified
atmosphere. The next day, L15+ was replaced with neurobasal
media, NBM (GibcoBRL 21103-049, Invitrogen Inc., New York,
USA), containing 1:50 B-27 (GibcoBRL 17504-044, Invitrogen
Inc., New York, USA), 10 IU/ml PenStrep, and 9% NaCl2 (Sigma
S-3014, Sigma-Alderich Chemie GmbH, Steinheim, GE), and
marked as NBM+. Cells were incubated for 7 days until the neurons
extended neurites and became mature. The neuron/glia culture
ratio was determined by immunofluorescent labeling with neuronal
(Milli-Mark
TM Pan Neuronal Marker, Millipore MAB2300.,
Millipore Corp., California, USA) and glial (GFAP, Invitrogen
AB5804, Invitrogen Inc., New York, USA) markers, using Leica
Application Suite Image Overlay Software (Leica Microsystems
Ltd., Heerbrugg, GE) (Fig. 5).
Figure 4. siRNA-mediated knockdown of VDR leads to a significant reduction in NGF release. * VDR-silenced neurons had significantly
lower NGF release compared to control, vehicle, non-target siRNA and cycB siRNA-treated groups (p,0.05, p,0.01, p,0.01, p,0.01, respectively).
Data are presented as a mean SD.
doi:10.1371/journal.pone.0017553.g004
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To determine the time it took to knockdown VDR mRNA and
protein levels, three different time periods for VDR siRNA
treatment (6, 12 and 24 hours) were tested in cortical neurons.
Commercially available VDR siRNAs (ON-TARGET plus
SMART pool Rat VDR, NM_017058 siRNA, Dharmacon L-
097753-01-0010., Dharmacon Inc., Colorado, USA) were ob-
tained from the manufacturer. Cyclophiline B siRNAs (ON-
TARGET plus SMART pool Rat Cyclophiline B siRNA,
Dharmacon D-001820, Dharmacon Inc., Colorado, USA) and
non-target siRNAs (ON-TARGET plus SMART pool Rat Non-
Target siRNA, Dharmacon D-001810, Dharmacon Inc., Colora-
do, USA) were used as the positive and negative controls,
respectively. As additional controls, untreated cells and cells
treated with only transfection reagent were used. DHARMA-
FECTH 3 (Dharmacon T-2003-02, Dharmacon Inc., Colorado,
USA) transfection reagent was used for transfection. All transfec-
tions were performed on neurons that had been cultured for 7
days. After treatment, the transfection media was replaced with
NBM+ including antibiotics. All RNA isolations were performed
24 hours after the applications.
Vitamin D (1,25 (OH)2D3) application
To detect the effect of vitamin D on supressed VDR expression,
the earliest time point after siRNA treatment was 12 hours. VDR
siRNA-transfected cortical neurons (following 12 hours of VDR
siRNA treatment) were incubated with vitamin D (1,25 (OH)2D3,
Sigma C-9756, Sigma-Alderich Chemie GmbH, Steinheim, GE)
for 12 hours. The final concentration of vitamin D (1610
27 M) in
culture was determined from the preliminary results.
Cytotoxicity and cell death assay
Cytotoxicity levels were determined by measuring the amount
of Lactate dehydrogenase (LDH) released into the culture media
using a Cytotoxicity Detection Kit (Roche 11644793001, Roche
Diagnostics GmbH Roche Applied Science Mannheim, GE) by
ELISA according to the manufacturer’s protocol. Each sample was
tested in triplicate.
Cell death was determined using an In Situ Cell Death
Detection Kit, Fluorescein (Roche 11684795910, Roche Diagnos-
tics GmbH Roche Applied Science Mannheim, GE) according to
the manufacturer’s protocol. TUNEL-positive and TUNEL-
negative cells were determined by overlaying fluorescent and
phase contrast micrographs using Leica Application Suite Image
Overlay Software.
Quantitative-real time polymerase chain reaction (qRT-
PCR)
RNA was isolated from cultured neurons using a High Pure
RNA Isolation Kit (Roche 11828665001, Roche Diagnostics
GmbH Roche Applied Science Mannheim, GE). cDNA was
prepared using a Transcriptor First Strand cDNA Synthesis Kit
(Roche 04379012001, Roche Diagnostics GmbH Roche Applied
Science Mannheim, GE). VDR, LVSCC-A1C, LVSCC-A1D and
Cyclophilin B mRNA levels in cortical neurons were analyzed
using qRT-PCR, Universal Probe Library (UPL) probes, a
Lightcycler 480 Probe Master Mix kit (Roche 04707494001,
Roche Applied Biosystems
TM, California, USA) and a LIGHT-
CYCLER 480 (Roche Applied Biosystems
TM California, USA).
All primers and probes were chosen from Roche’s UPL system as
follows: VDR, NM_017058.1, UPL Probe #.65 (Roche
04688643001, Roche Applied Biosystems
TM, California, USA);
LVSCC-A1C, NM_012517.2 UPL Probe #73 (Roche
04688961001, Roche Applied Biosystems
TM, California, USA);
LVSCC-A1D, NM_017298.1 UPL Probe #82 (Roche
04689054001, Roche Applied Biosystems
TM, California, USA)
and Cyclophilin B, NM_022536.1, UPL Probe #97 (Roche
04692144001, Roche Applied Biosystems
TM, California, USA).
GAPDH (GAPDH Gene Assay, Roche 05046203001, Roche
Applied Biosystems
TM, California, USA), Beta actin (ACTB Gene
Assay, Roche 05046203001, Roche Applied Biosystems
TM,
California, USA) and HPRT (HPRT NM_012583.2 UPL Probe
#95, Roche 04692128001, Roche Applied Biosystems
TM, Cali-
fornia, USA) were used as endogenous reference genes to
normalize mRNA levels for qRT-PCR [38]. Five control sample
serial dilutions were used to calculate the PCR efficiency. Reaction
mixtures without cDNA template were utilized as negative
controls. For each group, six dishes (6610
5 cells per dish) were
used to extract mRNA. For each group, mRNA isolations were
performed three times, and qRT-PCR was repeated two times for
each sample in one experiment. The experiment was repeated
three times.
Western blot
Total protein extracts were prepared from 2610
6 cells with M-
PER Mammalian Protein extraction reagent (Thermo Scientific
78501, Thermo Fisher Scientific Inc. Illinois, USA) according to
the manufacturer’s protocol. Prior to extraction, 1x Halt Protease
Inhibitor Cocktail (Thermo Scientific 78429), 17 mg/ml Calpain
Inhibitor I (Roche 11086090001, Roche Applied Biosystems
TM,
California, USA) and 7 mg/ml Calpain Inhibitor II (Roche
11086103001, Roche Applied Biosystems
TM, California, USA)
were added to the extraction reagent. Nuclear proteins were
extracted from 2610
6 cells using NE-PER Nuclear and Cytoplas-
mic Extraction Reagent (Thermo Scientific 78833, Thermo Fisher
Scientific Inc. Illinois, USA) according to the manufacturer’s
protocol. Prior to extraction, 1x Halt Protease Inhibitor Cocktail
was added to the extraction reagent. Protein concentrations were
assessed using a Picodrop
TM (Picodrop Limited, Saffron Walden,
UK). Briefly, 50 mg of proteins from cell homogenates were
separated by electrophoresis through a precast NovexH 4–20%
Tris-Glycine Gel (Invitrogen EC6028BOX, Invitrogen Inc., New
York, USA). Proteins were then transferred to PVDF membrane
using an IBlot Dry Blotting System (Invitrogen Inc., New York,
USA). PVDF membranes were blocked with 5% dry milk over
night at 4uC, incubated with primary antibodies over night at 4uC,
then incubated in secondary antibodies for 2 hours at room
temperature. PVDF membranes, containing proteins from nuclear
extracts, were incubated with a vitamin D receptor rat monoclonal
antibody (Chemicon, Millipore MAB1360, Millipore Corp.,
Figure 5. Seven-day-old primary cortical neurons were used to
determine the neuron/glia ratio. The glia ratio was 10% in cultured
cells. Neurons, green (FITC tagged PAN neuronal marker antibody); Glia,
red (Texas Red (TR) tagged GFAP antibody). 40X magnification.
doi:10.1371/journal.pone.0017553.g005
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horseradish peroxidase (HRP)-conjugated goat anti-rat secondary
antibody (Chemicon, Millipore AP136P, Millipore Corp. Califor-
nia, USA) at a 1:3,000 dilution. All other PVDF membranes,
including total protein extracts, were incubated with a LVSCC-
A1C rabbit polyclonal antibody (Abcam Ab58552, Abcam Inc.,
Massachusetts, USA) and LVSCC-A1D rabbit polyclonal anti-
body (Abcam Ab54421, Abcam Inc., Massachusetts, USA) at a
1:3,000 dilution, following incubation with HRP-conjugated goat
anti-rabbit secondary antibody (Abcam Ab6721, Abcam Inc.,
Massachusetts, USA) at a 1:3,000 dilution. A 1:5,000 dilution of
Beta actin rabbit polyclonal antibody (Abcam Ab8227, Abcam
Inc., Massachusetts, USA) was used as a loading control. Signals
were detected using a Lumi-Light
PLUS Western Blotting Substrate
(Roche 12 015 196 001, Roche Applied Biosystems
TM, California,
USA). Each sample was tested in duplicate, and western blots were
repeated three times.
NGF assay
The amount of NGF secreted into culture media was
determined using a Chemikine Nerve Growth Factor (NGF)
Sandwich ELISA kit (Chemicon CYT304, Millipore Corp.,
California, USA) by ELISA. Each sample was tested in triplicate,
and each test was replicated.
Statistics
Ct values obtained from qRT-PCR were calculated by the
DCt=2
(Geometric mean of reference genes - Ct target gene) formula for
determining relative target gene expression levels. Microsoft Office
Excel wasutilized to perform the calculations and produce graphics.
The results were compared withone-way ANOVA using GraphPad
InStat DTCG 3.06 (GraphPad Software, Inc., San Diego, USA),
and p,0.05 was considered to be statistically significant. Data are
represented as mean standard deviations (SD).
A more sophisticated analysis for qRT-PCR results was
performed using the Relative Expression Software Tool, REST
2008 (Corbett Research Pty LtD and Michael Pfaffl, New South
Wales, AU), which has an algorithm for PCR efficiency,
normalization and 95% confidence interval calculations. Reaction
efficiencies were calculated using five different cDNA template
dilutions. The software’s hypothesis test, P(H1), determines the
probability that the difference between two groups is due to
chance. Thus, a P(H1) ,0.05 indicates that there is a significant
difference between the two groups, and the probability that this
difference is due to chance is less than 5%. REST 2008 and
ANOVA results were consistent with each other.
Comparisons of western blot band intensities were calculated
using Image J 1.44a software (Wayne Rasband, National Institute
of Health, USA). This program calculates the absolute intensity
value for each protein band by measuring area and pixel values.
The target protein absolute intensity relative to Beta actin absolute
intensity ratio is defined as the ‘‘band intensities relative to Beta
actin,’’ and was used to compare protein expression between each
group. The relative protein expression of each group was
compared using GraphPad InStat DTCG 3.06 one-way ANOVA
method, and a p,0.05 was considered to be statistically
significant. Data are presented as a mean SD.
Each ELISA sample was read three times, and the mean values
were used in percentage calculations. Negative control mean values
were subtracted from the sample and control group mean values.
Cytotoxicity levels were compared to control groups. Calculations
were made according to the formula given below, and Microsoft
Office Excel was used to create the graphic: Cytotoxicity (%) =
[(expected value – low control)/(high control - low control)] x100.
NGF concentration were calculated using standard curve
(R
2=0.94) and the data were presented as %NGF. Raw data for
each group was analyzed using the GraphPad InStat DTCG 3.06
one-way ANOVA method, and a p,0.05 was considered to be
statistically significant. NGF data were given as the mean SD.
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